Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...

Cambridge, Massachusetts – home to Harvard and MIT – was the primary source of Chinese researchers who chose to head home.

A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

Louisiana’s surgeon general said in a memo Thursday that the state would “encourage each patient to discuss the risks and benefits of vaccination with their provider” but would “no longer promote mass ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...